Vaccine Development Overview

Principles

Definition

Vaccine development is a complex, multi-disciplinary research field and process dedicated to the discovery, design, preclinical and clinical testing, and large-scale manufacturing of vaccines. This endeavor aims to induce protective immunity against infectious diseases or other medical conditions by safely stimulating the host's immune system.

Ontological type

Clinical Trial Phases

Vaccine Platforms

Antigen Selection

Key developments

Key Figures

Adjuvant and Safety Shift era

Robert M. Chanock [1], associated with Johns Hopkins University [3] and University of Maryland, Baltimore [4], stood as a leading figure in vaccine research during the Adjuvant and Safety Shift era. His key contributions in this era centered on understanding the safety and immunogenicity of inactivated vaccines, as illustrated by RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE12 [7], which highlighted limitations of early platforms and the need for adjuvant-driven strategies to enhance protection while controlling reactogenicity. Robert H. Parrott [2], associated with Georgetown University [5] and George Washington University [6], contributed to the era by advancing safety testing concepts and adjuvant-oriented formulation approaches. The same RSV vaccine study [7] exemplifies how safety-focused assessment and antigenic orientation informed strain selection and platform decisions, shaping adjuvant use and vaccine design to balance efficacy with acceptable reactogenicity.

Antigen Design and Delivery era

John Donnelly [1], affiliated with Johns Hopkins University [3] and the United States Military Academy [4], played a formative role in vaccine design developments. His key contribution was the paper Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein [6], demonstrating that DNA encoding a viral protein could elicit heterologous protection and underscoring the potential of programmable antigen delivery. Jeffrey B. Ulmer [2], associated with United States Military Academy [4] and Yale University [5], contributed to early DNA vaccination work. Ulmer [2] contributed as a co-author of Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein [6], illustrating early DNA vaccine concepts and informing safety and regulatory considerations for platform development.

Platform and Structure Integration era

Cosette M. Wheeler [1] was affiliated with University of California, San Francisco [3] and Johns Hopkins University [4] during this era. Wheeler [1] contributed through pivotal randomized controlled trials of HPV L1 virus-like particle vaccines, including the bivalent L1 VLP vaccine trial [6] and the quadrivalent L1 VLP vaccine trial [7], which demonstrated protective efficacy and helped translate findings into public health recommendations [8]. Mona Saraiya [2] worked with University of California, San Francisco [3] and University of Puerto Rico at Carolina [5] during this era. Saraiya [2] contributed to policy development, notably the Quadrivalent HPV vaccine ACIP recommendations [8], which anchored immunization strategies in this era and facilitated rapid regulatory translation.